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1494Background: ATS Medical, Inc, developed a mechanical heart valve that has been in use since 1992. In this
article, we present the results of 15 years of follow-up of patients who have undergone ATS heart valve replace-
ment at our hospital.
Methods and Results: We performed ATS heart valve replacements on 231 patients between September 1993
and March 2008. Our operative mortality rate for the study period was 2.2%. The survival for postoperative
thromboembolic events was 0.29%/pt-y for aortic valve replacement, 0.48%/pt-y for mitral, 0.80%/pt-y for dou-
ble valve replacement, and overall 0.44%/pt-y. The survival after bleeding events was 0.29%/pt-y for aortic
valve replacement, 0.16%/pt-y for mitral, 0%/pt-y for double valve replacement, and overall 0.19%/pt-y.
Patient–prosthesis mismatch, as determined by echocardiography, was found in 83.3% of patients at 19 mm,
but other sizes showed good valve function. Prosthetic valve noise was undetectable in 92.8% of patients, and
quality of life was excellent.
Conclusions: Few prosthetic valve–related complications were seen with ATS heart valve replacements in this
study, and the follow-up results were favorable. The international normalized ratio was maintained in the range
1.6 to 2.0 in patients with aortic valve replacement in sinus rhythm. Not only bleeding events, seen at a rate of
0.19%/pt-y, but also thromboembolic events, at 0.44%/pt-y, were low when compared with conventional me-
chanical valves. Prosthetic valve noise is low, and this appears to be an excellent mechanical valve from the qual-
ity of life standpoint. The ATS valve has an excellent safety profile when compared with other mechanical valves.
(J Thorac Cardiovasc Surg 2010;139:1494-500)The ATS valve (ATS Medical, Inc, Minneapolis, Minn) has
an expanded valve orifice area, inasmuch as the entire orifice
is made of pyrolytic carbon material, with increased durabil-
ity. It has a superior safety profile, in terms of antithrombotic
and hemolytic effects, in comparison with conventional
prosthetic valves. It was developed as a bileaflet valve and
is used around the world.1,2 The first bileaflet valve to be
developed was the St Jude Medical (SJM) valve, which
was released in 1977 (St Jude Medical Inc, St Paul, Minn).
It has excellent hemodynamics with central flow, and good
follow-up results made it the highest-rated mechanical valve
in the world.3-5 At our hospital, we have used the SJM valve
since 1978, when it was implanted in the first Japanese
patient, and we have achieved reliable results.6,7 Over an
observation period of more than 10 years, thromboembolic
events have been reported to occur at a rate of 0.20% to
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The Journal of Thoracic and Cardiovascular Surbleeding events at 0.45% to 3.5%/pt-y, but the results
vary among institutions.4-9
The ATS mechanical heart valve was first used in valve re-
placement surgery in May 1992, and its first use in Japan was
at our hospital in September 1993. It was licensed by the Min-
istry of Health, Labour and Welfare in July 1996 and came into
general use thereafter. There have been several case reports
concerning this valve, confirming its usefulness, but few re-
ports on follow-up results. In this article, we present the results
of 15 years’ follow-up with the ATS valve at our hospital.PATIENTS AND METHODS
Patient Population
Between September 1993 and March 2008, 238 patients underwent
valve replacement with the ATS valve at the Nihon University Itabashi Hos-
pital, and we were able to follow up 231 of these patients, excluding those
who underwent tricuspid valve replacements. At our hospital, the valve of
choice was the SJM valve from 1978 and the ATS valve from 1993. Since
2006, both valves have been used in tandem. Mechanical valves are gener-
ally used only for patients less than 70 years of age at our hospital. However,
when a patient is more than 70 years old and a 19-mm bioprosthetic valve
cannot be implanted, a mechanical valve is selected when it is judged that
the patient should have an 18-mm or smaller valve for better quality of
life (QOL) in consideration of his/her general preoperative condition, rather
than undergoing aortic root enlargement to allow implantation of a biopros-
thetic valve. This study was approved by the Ethics Committee of Nihon
University Itbashi Hospital and was registered with the University Hospital
Medical Information Network (Study No. ID: 000001636). Final examina-
tions were conducted in February 2009. The age of the patients ranged from
14 to 83 years (mean 57.3 11.6 years), including 19 (8.3%) patients whogery c June 2010
TABLE 1. Preoperative data
Sezai et al Acquired Cardiovascular DiseaseAVR MVR DVRAbbreviations and AcronymsNo. 103 92 36AP ¼ advanced performance
Age (y) 57.7  13.7 56.7  10.6 57.9  7.0AVR ¼ aortic valve replacement
Gender (male/female) 78:25 43:49 22:14DVR ¼ double valve replacement (AVRþMVR)
DiagnosisLDH ¼ lactic acid dehydrogenase
AorticMVR ¼ mitral valve replacementStenosis 21 — 7PPM ¼ prosthesis–patient mismatch
Regurgitation 60 — 13PVL ¼ paravalvular leakage
Combined 20 — 16QOL ¼ quality of life
Prosthetic valve dysfunction 2 — 0
Mitral
SJM ¼ St Jude MedicalStenosis — 20 10
Regurgitation — 51 13
Combined — 16 13
Prosthetic valve dysfunction — 5 0
Reoperation 5 13 2
NHYA class
I 1 0 0
II 23 36 3
III 51 52 20
IV 18 14 13
AVR, Isolated aortic valve replacement; MVR, isolated mitral valve replacement; DVR,
double valve replacement; NHYA, New York Heart Association.
TABLE 2. Prosthetic valve size and body surface area
Patient numbers BSA (m2)
AVR
16 mm AP 1 1.35
18 mm AP 15 1.43  0.08
19 mm 6 1.48  0.19
20 mm AP 10 1.46  0.15
21 mm 25 1.54  0.17
22 mm AP 0 —
23 mm 45 1.67  0.17
24 mm AP 4 1.77  0.30
25 mm 17 1.74  0.12
27 mm 16 1.75  0.13
MVR
23 mm 1 1.50
25 mm 11 1.45  0.20
27 mm 58 1.53  0.15
29 mm 46 1.62  0.20
31 mm 12 1.65  0.27
AVR, Aortic valve replacement; AP, advanced performance; BSA, body surface area;
MVR, mitral valve replacement.
A
C
Dwere aged 70 years or greater. There were 143 men and 88 women. The pro-
cedure was an isolated aortic valve replacement (AVR) in 103 patients, iso-
lated mitral valve replacement (MVR) in 92, and AVRþMVR (DVR) in 36.
Other procedures performed simultaneously included the maze operation in
20 patients, coronary artery bypass in 25, tricuspid valvuloplasty in 14, re-
placement of the ascending aorta in 4, and left ventricular aneurysmectomy,
atrial septal defect patch closure, and ventricular septal defect closure in 1
each. Twenty procedures were reoperations (Table 1). The sizes of the valve
used and body surface areas are shown in Table 2.
Operative Technique
Procedures were performed with patients on cardiopulmonary bypass
with moderate hypothermia using cold crystalloid cardioplegic solution (St
Thomas’ Hospital solution). All valve replacements were performed with
simple interrupted stitches with 2-0 Ethibond sutures (Ethicon, Inc, Somer-
ville, NJ). The valve was positioned perpendicular in axis to the septum in
AVR procedures and placed in an antianatomic position in MVR procedures.
Transthoracic Echocardiography
Postoperative valve function was evaluated on the basis of stability at 6
to 12 months postoperatively, using transthoracic echocardiography. Spe-
cialists in echocardiography performed all examinations. For MVR proce-
dures, the continuous Doppler wave method was used to measure peak
velocity and mean velocity in the left ventricular inflow region. The peak
and mean pressure gradients were calculated by the simplified Bernoulli for-
mula. For AVR procedures, the continuous Doppler wave method was used
to measure peak velocity and mean velocity in the aortic valve distal region,
from which the peak and mean pressure gradients were calculated. The ef-
fective orifice area of the artificial valve was calculated from the pressure
half-time for the mitral valve and from the modified continuity equation
for the aortic valve. The effective orifice area was divided by the body sur-
face area, and the effective orifice area index was calculated. For the aortic
valve, the effective orifice area index showed moderate prosthesis–patient
mismatch (PPM) at 0.66 to 0.85 and severe PPM at less than 0.65. Measured
values were all the average over 10 consecutive heartbeats.
Hemolysis
Serum lactic acid dehydrogenase (LDH) and haptoglobin levels were
measured at 6 months postoperatively as indices of postoperative hemolysis.
Deaths, including operative deaths within 6 months postoperatively, and pa-
tients with paravalvular leakage (PVL) confirmed by echocardiography, and
patients with previous surgery were excluded. None of the patients had un-
dergone blood transfusion within 1 month and none of them had diseases
that could increase LDH (such as gallstones) at 6 months after surgery.
Evaluation of Prosthetic Valve Noise
Patients were interviewed regarding prosthetic valve noise at 6 months
postoperatively. Early deaths and deaf patients were excluded. TheThe Journal of Thoracic and Carfollowing questions were asked: (1) Do you hear a prosthetic valve sound
(audible)? For patients who do hear something, (2) do you sometimes hear
it (sometimes disturbance)? (3) Does it disturb your daily life (daytime dis-
turbance)? (4) Does it disturb your sleep (sleep disturbance)? (5) If there
was a prosthetic valve with no noise, would you want to exchange it for
your present valve (prefers less noisy valve)? For part 4, the noise index
is an indicator of patient stress caused by prosthetic valve noise that we
proposed in an earlier paper.10 The level of stress is expressed numerically,
with maximum stress assigned 10 points and 0 points when no stress at all




Acquired Cardiovascular Disease Sezai et alFollow-up
Postoperative anticoagulant therapy or antiplatelet therapy comprised
warfarin, aspirin (100 mg/day), or dipyridamole (200 mg/day). The interna-
tional normalized ratio was maintained at 1.6 to 2.0 in AVR patients, 1.8 to
2.5 in MVR patients, and 2.0 to 2.5 in DVR patients, patients with atrial
fibrillation, and patients with a left atrial diameter of 50 mm or more.
Postoperatively, patients were seen once a month as outpatients. Postop-
erative event evaluations were based on the valvulopathy postoperative
evaluation guidelines of The American Association for Thoracic Surgery,
the European Association for Thoracic Surgery, and the Society of Thoracic
Surgeons.11
Statistical Analysis
The actuarial survival and postoperative complication-free rate were
evaluated by the Kaplan–Meier method, and differences between groups
were assessed by the log–rank test. Numerical values were expressed as
mean  standard deviations.FIGURE 1. Actuarial survival curves. AVR, Isolated aortic valve
replacement; MVR, isolated mitral valve replacement; DVR, double valve
replacement.RESULTS
Follow-up
Follow-up was not possible for 2 patients, yielding a fol-
low-up rate of 99.1%. The average follow-up period was
6.93  3.77 years, the longest being 15.3 years. A total of
1601.7 patient-years were performed.
Early mortality and causes of death. There were 5 deaths
within 30 days postoperatively (2.2%): 2 after AVR (1.9%),
1 after MVR (1.1%), and 2 after DVR (5.6%). There were 5
deaths within 60 days postoperatively (2.2%): 2 after AVR
(1.9%), 1 after MVR (1.1%), and 2 after DVR (5.6%).
There were 5 deaths within 90 days postoperatively
(2.2%): 2 after AVR (1.9%), 1 after MVR (1.1%), and 2 af-
ter DVR (5.6%). All early deaths occurred in the hospital.
The cause of death was low cardiac output syndrome in 3
cases and acute renal failure, acute heart failure, cerebral
hemorrhage, and graft-versus-host disease in 1 case each.
After detection of complications, patients underwent transe-
sophageal or transthoracic echocardiography. Since PVL
was detected in the patient who eventually died of graft-ver-
sus-host disease, the operation was repeated. Autopsies were
performed on 2 patients who died of low output syndrome,
as well as those who died of acute heart failure, cerebral
hemorrhage, and graft-versus-host disease (autopsy rate:
71.4%). No prosthetic valve–related complications, such
as PVL, were found at autopsy.
Late mortality and causes of death. There were 25
deaths, including 12 after AVR, 10 after MVR, and 3 after
DVR. The cause of death was malignant disease in 8 pa-
tients, heart failure in 6, sudden death, arrhythmia, and acute
renal failure in 2 each, and cerebral infarction, miliary tuber-
culosis, septicemia, pneumonia, and thoracic aortic rupture
in 1 each. Autopsies were performed in the 2 sudden deaths,
2 patients who died of arrhythmia, and 1 each of miliary
tuberculosis, septicemia, pneumonia, and thoracic aortic
rupture (autopsy rate: 32%). No abnormal findings related
to the prosthetic valves were found at autopsy. The other
patients underwent transesophageal or transthoracic1496 The Journal of Thoracic and Cardiovascular Surechocardiography, but no prosthetic valve–related compli-
cations were found. The cumulative survival, including early
mortality, was 91.8% 2.8% at 5 years, 84.8% 4.8% at
10 years, and 59.1%  17.9% at 15 years after AVR;
91.2%  3.0% at 5 years, 89.8%  3.3% at 10 years,
and 76.9%  12.2% at 15 years after MVR; and 83.3%
 6.2% at 5 years, 79.7%  6.9% at 10 years, and
79.7%  6.9% at 15 years after DVR (Figure 1).
Valve-related mortality. Cerebral hemorrhage occurred in
1 patient, and PVL occurred in 1 patient with early mortality
owing to graft-versus-host disease, 2 with cerebral infarc-
tion, and 2 patients with late mortality owing to sudden
death, for a total of 6 (2.6%) patients.
Valve-related complications: Nonstructural dysfunc-
tion. PVL occurred in 2 patients apart from the 1 fatal
case. One patient underwent reoperation, and the other had
an LDH of 721 IU/L and was observed without another op-
eration. The nonstructural dysfunction–free rate was 100%
at 5 years, 100% at 10 years, and 100% at 15 years after
AVR; 100% at 5 years, 100% at 10 years, and 100% at
15 years after MVR; and 94.0%  4.1% at 5 years,
89.5%  5.9% at 10 years, and 89.5%  5.9% at 15 years
after DVR. The survival was 0%/pt-y after AVR, 0%/pt-y
after MVR, 1.20%/pt-y after DVR, and 0.19%/pt-y for all
patients.
Thromboembolic disease. In addition to the 1 death owing
to cerebral infarction, there were 3 other cases of cerebral in-
farction, 1 of transient ischemic attack, and 2 of left atrial
thrombosis for a total of 7 thromboembolic events. Of the
4 patients having cerebral infarction, 1 died, 2 recovered
with no aftereffects, and 1 had lingering paresis. One patient
with left atrial thrombosis underwent a second operation,
and the blood clot was removed by thrombolysis in the other.gery c June 2010
FIGURE 2. Freedom from thromboembolic events. AVR, Isolated aortic
valve replacement; MVR, isolated mitral valve replacement; DVR, double
valve replacement.
FIGURE 3. Freedom from bleeding events. AVR, Isolated aortic valve re-
placement; MVR, isolated mitral valve replacement; DVR, double valve re-
placement.
FIGURE 4. Freedom from valve-related complications. AVR, Isolated aor-





Sezai et al Acquired Cardiovascular DiseaseThe patient who underwent a second operation was a 32-
year-old woman. She had undergone MVR with an SJM
valve previously, but MVR was repeated because of left
atrial thrombosis and PVL. She had a giant left atrium (left
atrial diameter: 80 mm). After plication, the postoperative
left atrial diameter was 70 mm. Inasmuch as a massive
thrombus developed in the left atrium at 3 years 5 months
postoperatively, thrombectomy was performed. No abnor-
malities of the ATS valve were found and replacement
was not necessary. At present, 7 years have passed since
the second operation, but no further thrombus has been de-
tected in the left atrium. The patient who did not undergo
an operation was a 71-year-old woman. She had undergone
DVR, and a 20-mm thrombus was found in the left atrium by
transesophageal echocardiography on day 10 postopera-
tively. Because the thrombus was small and there were no
abnormalities of the ATS valve itself, thrombolysis with tis-
sue plasminogen activator was performed and the thrombus
disappeared. At present, 5 years have passed since this pro-
cedure and no further thrombi have been detected in the left
atrium. In both patients, atrial fibrillation and marked left
atrial hypertrophy were observed.
The thromboembolic event–free rate was 98.0%  1.4%
at 5 years, 98.0% 1.4% at 10 years, and 98.0% 1.4% at
15 years after AVR; 98.6%  1.3% at 5 years, 98.6% 
1.3% at 10 years, and 98.6%  1.3% at 15 years after
MVR; and 93.3%  4.6% at 5 years, 93.3%  4.6% at
10 years, and 93.3%  4.6% at 15 years after DVR. The
survival was 0.29%/pt-y after AVR, 0.48%/pt-y after
MVR, 0.80%/pt-y after DVR, and 0.44%/pt-y for all
patients (Figure 2).
Bleeding events. In addition to 1 early death owing to
cerebral hemorrhage, 2 patients had cerebral hemorrhagesThe Journal of Thoracic and Carduring the follow-up period for a total of 3 bleeding events.
One patient recovered with no aftereffects, and the other had
lingering paresis. The bleeding event–free rate was 98.0%
 1.4% at 5 years, 98.0%  1.4% at 10 years, and
98.0%  1.4% at 15 years after AVR; 100% at 5 years,
100% at 10 years, and 75.0%  2.2% at 15 years after
MVR; and 100% at 5 years, 100% at 10 years, and 100%
at 15 years after DVR. The survival was 0.29%/pt-y after
AVR, 0.16%/pt-y after MVR, 0%/pt-y after DVR, and
0.19%/pt-y for all patients (Figure 3).
Other valve-related complications. No structural valve
deterioration, valve thrombosis, or operative valve endocar-




Acquired Cardiovascular Disease Sezai et alThe total valve-related complication-free rate was 96.0%
 1.9% at 5 years, 93.0%  2.8% at 10 years, and 93.0%
 2.8% at 15 years after AVR; 98.6%  1.3% at 5 years,
97.0% 2.1% at 10 years, and 72.8% 21.1% at 15 years
after MVR; and 87.4%  5.9% at 5 years, 83.2%  6.9%
at 10 years, and 83.2%  6.9% at 15 years after DVR. The
survival was 0.72%/pt-y after AVR, 0.79%/pt-y after
MVR, 1.94%/pt-y after DVR, and 0.95%/pt-y for all pa-
tients (Figure 4).
Echocardiographic results. The results of transthoracic
echocardiographic evaluation of prosthetic valve function
are shown in Table 3. Moderate PPM was found in 1
(100%) patient with a 16-mm AP (advanced performance)
valve, in 3 (21.4%) of 14 with 18-mm AP valves, in 4
(66.7%) of 6 with 19-mm valves, in 1 (10%) of 10 with
20-mm AP valves, in 1 (4.2%) of 24 with 21-mm valves,
in 5 (11.1%) of 45 with 23-mm valves, and in no patients
with 24-mm AP, 25-mm, or 27-mm valves. Serious PPM
was found in no 16-mm AP or 18-mm AP valves, in 1
(16.7%) of 6 19-mm valves, in no 20-mm AP or 21-mm
valves, in 2 (4.4%) of 45 23-mm valves, and in no 24-mm
AP, 25-mm, or 27-mm valves.
Hemolysis. LDH values at 6 months postoperatively were
218.3  42.3 IU/L (range 154–341 IU/L) after AVR,
247.5  58.5 IU/L (158–442 IU/L) after MVR, and 297.8
 85.6 IU/L (180–596 IU/L) after DVR. Patients falling
within the normal range (220 IU/L or less) comprised 63
(63.6%) after AVR, 38 (41.8%) after MVR, and 2 (7.1%)
after DVR. Haptoglobin levels stayed within the normal
range for all patients.
Prosthetic valve noise survey. A total of 16 (7.2%)








16 mm AP 30.4 16.5 1.01 0.75
18 mm AP 22.1  8.0 10.1  3.2 1.42  0.33 0.99  0.20
19 mm 38.8  11.0 18.5  5.3 1.07  0.12 0.75  0.09
20 mm AP 19.3  9.7 9.2  3.9 1.49  0.23 1.03  0.14
21 mm 23.8  10.5 10.2  4.3 1.65  0.36 1.07  0.24
22 mm AP — — — —
23 mm 18.3  9.5 8.6  5.5 1.76  0.46 1.07  0.28
24 mm AP 14.8  4.2 8.6  2.4 2.35  0.37 1.35  0.23
25 mm 18.8  6.9 7.9  3.5 1.81  0.34 1.05  0.21
27 mm 14.5  8.5 6.6  4.1 2.22  0.31 1.29  0.19
Mitral valve
23 mm 12.0 6.0 3.40 2.27
25 mm 8.8  3.1 3.1  1.6 2.68  0.87 1.92  0.82
27 mm 7.9  2.8 3.2  1.3 2.77  0.60 1.83  0.43
29 mm 7.2  3.0 3.0  1.5 3.07  0.66 1.96  0.43
31 mm 7.0  2.4 2.5  0.8 3.01  0.79 1.88  0.66
PPG, Peak pressure gradient; MPG, mean pressure gradient; EOA, effective orifice
area; EOAI, effective orifice area index; AP, advanced performance.
1498 The Journal of Thoracic and Cardiovascular Sursaying they were aware of prosthetic valve noise, compris-
ing 5 AVR, 5 MVR, and 6 DVR patients. However, all
patients responded that they ‘‘heard something but did not
notice it.’’ Prosthetic valve noise caused sleep disturbances
or disturbances in daily living in only a small number of pa-
tients. Among 16 patients who were aware of prosthetic
valve noise, 6 had undergone an operation in the past (valve
replacement in 3 and open mitral commissurotomy in the
other 3). Among the 3 patients with prior valve replacement,
the previous prosthetic valve was an SJM valve in 2 patients
and a Starr–Edwards ball valve in 1 patient. All 3 patients
considered that the ATS valve was less noisy than their pre-
vious mechanical valves.
The mean noise index was 0.22 0.61 points (0–3 points)
for all patients, 0.12  0.46 points (0–2 points) after AVR,
0.25 0.65 points (0–3 points) after MVR, and 0.40 0.70
points (0–3 points) after DVR.
DISCUSSION
This study is the first to present results of a 15-year fol-
low-up for ATS valves. We examined operative results, fol-
low-up results, prosthetic valve–related complications, and
echocardiographic evaluation of prosthetic valve function,
and the results were all satisfactory. A search of the literature
revealed only 2 reports with follow-up results for more than
10 years.12,13 Baykut and associates12 reported low levels of
valve-related complications at 1.1%/pt-y for thromboem-
bolic events, 0.5%/pt-y for bleeding events, 0.6%/pt-y for
PVL, and 0.04%/pt-y for valve thrombosis, with a mean fol-
low-up period of 4.3 2.5 years (longest 11 years). Stefani-
dis and colleagues13 reported 3 cases of thromboembolic
events as the only valve-related complications at a rate of
0.45/pt-y, with a mean follow-up period of 48  38 months
(longest 119 months). There were no other valve-related
complications, and the overall results were very favorable.
In terms of postoperative anticoagulant therapy, patients
with AVRs with sinus rhythm require a lower range of inter-
national normalized ratio than normal, at 1.5 to 2.5 accord-
ing to Westaby,1 Van Nooten,14 and their associates. Both
groups reported no problems with thromboembolic events.
In this study, patients in sinus rhythm after AVR were main-
tained at an international normalized ratio of 1.6 to 2.0, con-
siderably lower than the international standard. Not only was
the rate of bleeding events low at 0.19%/pt-y, but the rate of
thromboembolic events was also low at 0.44%/pt-y when
compared with results for conventional mechanical valves.
The reason for the low level of thromboembolic events
with ATS valves appears to be related to the structural ad-
vantage of reduction of blood stagnation, with the open pivot
inhibiting thrombosis.
We previously compared the results for the SJM, ATS,
and Starr–Edwards ball valves retrospectively in patients
who underwent MVR over the past 40 years at our hospital.




Sezai et al Acquired Cardiovascular Diseasedifferences among the valves, but the overall incidence of
valve-related complications was 2.99%/pt-y for the Star-
r–Edwards valve, 1.81%/pt-y for the SJM valve, and
0.77%/pt-y for the ATS valve, which was a significant dif-
ference. The ATS valve also showed good performance, as
did the SJM valve. However, this was not a randomized con-
trolled trial and there were differences in the chronological
characteristics of the groups. In the future, a randomized
controlled trial for comparison of each valve should be done.
Echocardiographic functional assessment of the ATS
valve shows low pressure gradients, other than for the 16-
mm AP and 19-mm models, and otherwise satisfactory re-
sults. The patient who required a 16-mm AP prosthesis
had a small annulus. She was an 83-year-old woman who
originally underwent an aortic root enlargement and then
had a valve replacement. Because her preoperative New
York Heart Association classification was grade IV and
her cardiac function was poor, aortic root enlargement was
not performed to shorten the operating time and a 16-mm
AP prosthesis was selected. Moderate PPM was observed
postoperatively, but her New York Heart Association classi-
fication improved to grade I, and there were no clinical prob-
lems. Use of 16-mm AP prostheses is limited. Severe PPM
occurs more often at 19-mm than other sizes, and when mod-
erate PPM is added, this size accounts for 83.3% of cases of
PPM. The AP series showed the same prosthetic valve func-
tion as the 3-mm size standard series. Aoyagi and associ-
ates15 evaluated the opening angles of various sizes of
ATS valves, reporting that 19-mm prostheses had a signifi-
cantly smaller opening angle than other sizes. Jazayeri and
colleagues16 evaluated the AP series using Doppler echocar-
diography. The peak pressure gradient was 23.5  5.3 mm
Hg for the 18-mm AP size, 21.43  4.18 mm Hg for the
20-mm AP, 18.67  8.31 mm Hg for the 22-mm AP, and
15.14  5.59 mm Hg for the 24-mm AP. The AP series
are supra-annular prosthetic valves that use the same hous-
ing as the standard series. Valves in the AP series have the
same orifice area as the 3-mm standard series because their
design means that the circumferential reinforced ring and
cuff are placed on the annulus. This is an excellent design
for small aortic annulus.
These results are basically in agreement with those ob-
tained in this study, and we consider the prosthetic valve
function of the AP series to be excellent. For the AP series,
a prosthesis no smaller than 18 mm, and for the standard se-
ries, no smaller than 21 mm, should be used wherever pos-
sible. If a smaller size is used, an aortic root enlargement
should be considered.
Westaby and colleagues1 reported that postoperative
LDH levels were 500 IU or less (normal range: 230–460
IU) in all patients. Shiono and coworkers17 reported that
LDH decreased at an earlier stage with ATS valves than
with SJM valves and normalized in patients with single
valve replacements. In this study, normalization occurredThe Journal of Thoracic and Carin 63.6% of patients after AVR and 41.8% after MVR. Af-
ter DVR, LDH levels were within the normal range in 7.1%
of patients, representing excellent results in terms of hemo-
lysis. The reasons for these results appear to be the absence
of struts, as found in SJM valves, and elimination of turbu-
lence in the pivot by using an open rather than closed pivot.
In patients undergoing valve replacement with mechani-
cal valves, dissatisfaction often arises due not only to pros-
thetic valve–related complications, but also prosthetic
valve noise. This is a very important factor in terms of
QOL, although few studies have addressed this topic. In
our hospital, we interviewed patients to evaluate their per-
ceptions of prosthetic valve noise. The noise index is an ‘‘in-
dicator of patient stress caused by prosthetic valve noise’’
proposed by the authors. It serves as an index for evaluation
of the QOL of patients with prosthetic valve replacements
using mechanical valves.10,18 In the present study, 92.8%
of patients were not aware of prosthetic valve noise, repre-
senting an excellent result in terms of QOL. In an earlier
study, we measured ATS prosthetic valve noise using inter-
views and high-sensitivity microphones, comparing it with
the SJM valve. The results of the interviews and the sound
pressure levels showed that the ATS valves are significantly
quieter than SJM valves. In terms of frequency characteris-
tics, ATS valve noise reaches a peak at about 1.2 kHz, and
the power decreases as the frequency increases. The SJM
valve also reaches a peak at about 1.2 kHz, and the power
decreases as the frequency increases, but to a lesser degree
that with the ATS valve. Strong components have been
found in the 2- to 5-kHz frequency range in which humans
show the greatest sensitivity, and this has an effect on
whether patients are aware of their prosthetic valve or
not.10 Heart rate and the opening angle also affect percep-
tions of prosthetic valve noise.18 ATS valves have been re-
ported to have smaller opening angles than SJM valves,19
a result confirmed at this hospital.18,20 In this study, cine-
fluoroscopy was not performed in all patients. Among the
50 MVR patients reported previously by the authors, only
7 (14%) patients showed complete 85 opening, whereas
there was 80 or more opening in 23 (46%) patients and
less than 80 in 27 (54%) patients. When we evaluated
whether the lack of complete opening to an angle of 85
had an adverse effect on prosthetic valve function by using
transthoracic echocardiography, we found that the angle
had no effect on prosthetic valve function.20 With a small
opening angle, the low stress when there is impact on the
valve may cause patients to be unaware of valve noise.
The fact that there is not complete opening at an opening an-
gle of 85 has an adverse effect on the hemodynamics and
prosthetic valve function, and problems arise if this leads
to an increase in valve-related complications. However,
the follow-up results in this study were entirely favorable,
and there appeared to be no problems. In the future, we




Acquired Cardiovascular Disease Sezai et alis a structural problem and whether the ATS valve is appro-
priate for use in all patient types.
CONCLUSION
This study revealed that the ATS valve showed no major
problems during long-term follow-up. There were few
valve-related complications and echocardiography showed
good valve function.
Prosthetic valve noise is low, and this appears to be an ex-
cellent mechanical valve from the QOL standpoint. The
ATS valve also has an excellent safety profile compared
with other mechanical valves.
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